Table 3 Comparison of patient characteristics for African American race and all other races combined for cases in which patients received additional reversal with Sugammadex

Age (years) (median [IQR])

63.1 [51.6, 72.1]

58.2 [48.8, 67.3]

Body mass index (kg/m²) (median [IQR])

30.08 [25.92, 35.19]

29.70 [25.66, 36.26]

ASA 1 or 2, n (%)

209 (16.3)

63 (16.7)

ASA 3

850 (66.3)

238 (63.0)

ASA 4

223 (17.4)

77 (20.4)

Inpatient (%)

429 (33.5)

135 (35.7)

Emergency case status, n (%)

284 (22.2)

111 (29.4)

Female, n (%)

602 (47.0)

175 (46.3)

Neuromuscular disease, n (%)

14 (1.1)

8 (2.1)

After hours cases, n (%)

94 (7.3)

41 (10.8)

End stage renal disease, n (%)

24 (1.9)

14 (3.7)

Case duration (min) (median [IQR])

169 [117, 252]

158 [108, 238]

Train of four

0 or 1, n (%)

530 (41.3)

165 (43.6)

2, 3, or 4

752 (58.7)

213 (56.3)

Surgical procedure types

Abdominal/General surgery

436 (34.0)

143 (37.8)

Burn surgery

13 (1.0)

2 (0.5)

Cardiac surgery

6 (0.5)

1 (0.3)

ENT surgery

117 (9.1)

31 (8.2)

Neurosurgery

62 (4.8)

6 (1.6)

Non-operating room anaesthesia

46 (3.6)

12 (3.2)

Orthopedic surgery

212 (16.5)

70 (18.5)

Plastic surgery

79 (6.2)

20 (5.3)

Thoracic surgery

67 (5.2)

12 (3.2)

Urogynecologic surgery

194 (15.1)

57 (15.1)

Vascular surgery

43 (3.4)

20 (5.3)

Other surgical procedures

7 (0.5)

4 (1.1)

Total rocuronium dose mg/kg/hr

0.48 [0.36, 0.67]

0.48 [0.36, 0.65]

Rocuronium redosed, n (%)

1012 (78.9)

277 (73.3)

Rocuronium dose > 0.43 mg/kg/hr (%)

1029 ( 60.0)

228( 60.3)

Primary reversal with neostigmine < 48 min after last dose of rocuronium

756 (63.3)

212 (56.1)

Neostigmine dose (mg/kg) (median [IQR])

0.05 [0.05, 0.06]

0.05 [0.04, 0.06]

Time between neostigmine and

sugammadex (min) (median [IQR])

12 [8, 18]

12 [7, 17]

Time between sugammadex and extubation (min) (median [IQR])

2 [1, 4]

2 [1, 5]